- GlobeNewswire•last monthAlbireo Completes Transaction with Biodel to Create Publicly Traded Company Focused on Orphan Pediatric Liver Diseases
—Albireo Pharma, Inc. to trade on The NASDAQ Capital Market under symbol“ ALBO”—. —Company to develop novel bile acid modulators to treat orphan pediatric liver diseases, other liver and gastrointestinal ...
- Insider Monkey•last month
So we’re going to close out the week with a roundup of some of the companies that have moved the most over the last couple of sessions, and what’s driving the movement. We’ll also take a stab at detailing what we expect moving forward for each – specifically, will the trend continue, or might the […]
- PR Newswire•last month
Biodel notes the following important considerations. The Further Adjournment would be intended to allow additional time for stockholders to vote on the proposals set forth in Biodel's definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on September 19, 2016. As of October 26, 2016, proxies have been submitted by stockholders representing approximately 49.83% of the outstanding shares of Biodel common stock outstanding and entitled to vote at the Annual Meeting, meaning that almost 32.2 million shares remain unvoted.
BIOD : Summary for ALBIREO PHARMA INC - Yahoo Finance
Biodel Inc. (BIOD)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Day's Range||0.52 - 0.71|
|52 Week Range||0.22 - 0.80|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.09|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|